Skip to content
StackItSmart
BHuman cohort / observational

Curcumin

Turmeric extract

Curcumin is the principal curcuminoid pigment of turmeric (Curcuma longa), sold as an ancillary "organ-support"/anti-inflammatory supplement. Used by adults for joint/arthritis pain, general anti-inflammatory and antioxidant effects, and metabolic support (glucose, lipids). Human RCTs and meta-analyses show modest, real reductions in inflammatory markers (CRP, IL-6, TNF-alpha) and improvements in some vascular and glycemic measures, so it is often perceived as harmless. The main risk is idiosyncratic drug-induced liver injury (DILI): a growing number of case reports and a US DILIN case series document hepatocellular injury, hospitalization, and at least one death from acute liver failure, strongly linked to the HLA-B*35:01 allele and often to high-bioavailability formulations combined with piperine (black pepper). Because plain curcumin is very poorly absorbed, many products deliberately boost absorption with piperine or lipid/nanoparticle delivery, which raises systemic exposure and appears to raise hepatotoxic risk. Other concerns are drug interactions via CYP inhibition (including anticoagulants), and iron chelation that can worsen iron-deficiency anemia. It is not an anabolic, hormonal, or performance drug. Anyone using it should treat new fatigue, dark urine, or jaundice as a stop-and-seek-care emergency and get baseline/periodic liver labs.

Clinical readoutAncillary · organ-support
Hepatic strainVery high
CardiovascularNone
HPTA suppressionNone
Half-life
1.5 h
Route
Oral
Evidence
B
Active
Effectively short at th…
1.5 h3 h4.5 h6 h7.5 h
Illustrative single-compartment washout · each mark = one half-life · t½ ≈ Short and variable; unconjugated curcumin is cleared over roughly 1-2 hours after oral dosing, with serum levels frequently undetectable. Piperine co-administration prolongs time-to-peak and reduces clearance/elimination.
Pharmacology

Mechanism of action

Curcumin is a polyphenolic diarylheptanoid that acts pleiotropically rather than on a single receptor. Its dominant proposed action is inhibition of the pro-inflammatory transcription factor NF-kB and downstream cytokines (TNF-alpha, IL-6, IL-1beta) and enzymes (COX-2, iNOS), plus direct antioxidant/free-radical scavenging and induction of the Nrf2 antioxidant response (raising total antioxidant capacity and superoxide dismutase, lowering malondialdehyde). It also chelates transition metals including iron. In human trials these mechanisms translate to lower circulating CRP, IL-6 and TNF-alpha. Curcumin additionally inhibits several cytochrome P450 enzymes (e.g., CYP1A2, CYP3A) and phase II glucuronidation in vitro, the basis for potential drug interactions. The mechanism of its idiosyncratic liver injury is not fully defined but is immune/HLA-mediated (strong HLA-B*35:01 association), consistent with an adaptive-immune, host-specific reaction rather than dose-dependent direct toxicity.
Kinetics

Pharmacokinetics

Half-life

Short and variable; unconjugated curcumin is cleared over roughly 1-2 hours after oral dosing, with serum levels frequently undetectable. Piperine co-administration prolongs time-to-peak and reduces clearance/elimination.

Active duration

Effectively short at the systemic level (hours); native curcumin does not accumulate. Sustained effects in trials rely on repeated daily dosing and possibly gut-level/metabolite activity rather than persistent plasma levels.

Route

Oral (capsules/powder/extracts). Marketed high-bioavailability forms use piperine, phospholipid/phytosome, micellar, or nanoparticle delivery to raise absorption.

Metabolism & clearance

Extensive first-pass metabolism in intestinal wall and liver via glucuronidation and sulfation to curcumin glucuronide/sulfate, plus reduction to tetrahydrocurcumin; low intrinsic oral bioavailability. Piperine inhibits hepatic/intestinal glucuronidation, increasing curcumin bioavailability by up to ~2000% in humans. Predominantly biliary/fecal elimination. Note: PK is described here for monitoring, interaction, and washout reasoning only.

For monitoring and washout planning, not drug-test evasion.

Reported effects

Physiological & performance effects

  • Reduces circulating inflammatory markers (C-reactive protein, IL-6, TNF-alpha) in adults across pooled RCT data
  • Improves antioxidant status (raises total antioxidant capacity and SOD, lowers malondialdehyde) in meta-analyzed trials
  • Modestly reduces knee osteoarthritis pain, with efficacy comparable to diclofenac in a head-to-head RCT and generally better GI tolerability
  • Improves some markers of endothelial function and lowers diastolic blood pressure and arterial stiffness (pulse wave velocity) in patients with metabolic disorders; systolic BP effect not significant
  • Lowers fasting blood glucose, HbA1c, and CRP modestly in people with type 2 diabetes in pooled trials
  • Poorly bioavailable on its own; perceived benefit is dose- and formulation-dependent and effect sizes are modest with heterogeneous, often low-quality evidence
Safety

Adverse effects by system

Cardiovascular

No cardiotoxic signal identified in human trials; pooled data trend neutral-to-beneficial (reduced diastolic BP, improved flow-mediated dilation, no significant systolic BP change). No arrhythmia, cardiomyopathy, or lipid-worsening signal reported.

Hepatic

Principal serious adverse effect. Idiosyncratic, usually hepatocellular drug-induced liver injury with latency of ~1-4 months, documented in case reports and a US DILIN case series (hospitalization in half, one death from acute liver failure). Strongly associated with the HLA-B*35:01 allele and with high-bioavailability/piperine-containing products. Italian pharmacovigilance also reported acute cholestatic hepatitis.

Endocrine / HPTA

Not a hormonal or androgenic agent. No evidence of hypothalamic-pituitary-gonadal axis suppression in humans; no adequate human data suggesting clinically meaningful endocrine disruption at supplement doses. Any hormonal concern should be directed to an endocrinologist.

Reproductive

No adequate human safety data in pregnancy or on fertility. Supplemental (above-food) doses are generally advised against in pregnancy due to lack of safety data and preclinical uterine-activity concerns; food-level culinary turmeric is not the same as concentrated extract.

Neuropsychiatric

No established adverse psychiatric effects; some trials study curcumin for mood with neutral-to-positive results. No adequate human data indicating psychiatric harm.

Renal

Purified curcumin has no established direct nephrotoxicity in human studies. Whole-turmeric powder is high in oxalate and carries a theoretical kidney-stone risk in susceptible people, but this has not been established for standardized curcumin extracts specifically; no adequate human data exist on renal harm from the extract.

Hematologic

Curcumin chelates iron; preclinical models show it can lower iron stores and cause mild anemia, so it may aggravate iron-deficiency anemia. A theoretical antiplatelet/bleeding tendency and interaction with anticoagulants exists (CYP inhibition shown in vitro), but robust human bleeding-outcome data are lacking.

Dermatologic

No significant dermatologic toxicity has been reported in human trials. Rare allergic or contact hypersensitivity to turmeric/curcumin is described anecdotally but is not substantiated by primary sources; no adequate human data exist on this potential harm.

Recovery

HPTA suppression & recovery

Suppression: None expected / not applicable. Curcumin is a non-hormonal polyphenol with no demonstrated HPTA (hypothalamic-pituitary-gonadal) suppression in humans.

No HPTA recovery protocol is indicated because there is no established suppression. This monograph does not endorse any SERM or post-cycle protocol for curcumin; SERMs are not relevant to a non-hormonal supplement. Any genuine concern about testosterone, gonadotropins, or hormonal recovery should be evaluated and managed by an endocrinologist with appropriate bloodwork, not self-directed.

Bloodwork & vitals

Monitoring

Recommended labs & checks
Baseline liver panel (ALT, AST, ALP, total bilirubin) before starting, especially for high-bioavailability or piperine-containing productsRepeat liver panel if any symptoms arise and periodically during prolonged useCBC and iron studies (ferritin, transferrin saturation) if using long-term or if at risk of iron deficiencyINR/coagulation monitoring if on warfarin or other anticoagulants

Cadence: Baseline, then roughly every 4-12 weeks during ongoing use or sooner with any warning symptom; check promptly (do not wait) if symptoms of liver injury appear.

Warning signs — seek care
  • Jaundice (yellowing of skin/eyes)
  • Dark urine or pale stools
  • Unusual fatigue, malaise, or loss of appetite
  • Right-upper-quadrant abdominal pain or nausea
  • Itching (pruritus)
  • Easy bruising or unusual bleeding
  • Worsening anemia symptoms (pallor, breathlessness, fatigue)
Do not use if

Contraindications

  • Known or prior curcumin/turmeric-associated liver injury, or any active/unexplained liver disease or elevated transaminases
  • Carriers of HLA-B*35:01 or a personal/family history of herbal/supplement-induced liver injury (higher idiosyncratic DILI risk)
  • Concurrent use of hepatotoxic drugs or heavy alcohol use
  • Use of anticoagulants/antiplatelet agents or narrow-therapeutic-index drugs metabolized by CYP1A2/CYP3A/glucuronidation without physician oversight
  • Iron-deficiency anemia or need to maintain iron stores (curcumin chelates iron)
  • Pregnancy and breastfeeding at supplemental doses (inadequate safety data)
  • Gallstones or biliary obstruction (turmeric stimulates bile flow)
  • Scheduled surgery (stop in advance due to theoretical bleeding/interaction risk) — coordinate with the surgical team
Combinations

Interaction profile

  • ContraindicatedWith DNP: Additive cardiovascular strain

Check a specific combination in the interaction checker.

Harm reduction

Reducing harm & when to stop

  • Get a baseline liver panel before starting, particularly for high-bioavailability, nanoparticle, or piperine (black-pepper) enhanced products, which raise systemic exposure and appear linked to liver injury.
  • Stop immediately and seek medical care for jaundice, dark urine, persistent nausea, right-upper-quadrant pain, or unusual fatigue — these can signal serious, occasionally fatal liver injury.
  • Prefer plain culinary/food-level turmeric use over concentrated high-dose extracts if the goal is general wellness; concentrated extract is not equivalent to spice.
  • Avoid combining with alcohol excess or other hepatotoxic drugs/supplements; disclose curcumin use to any clinician and before any surgery.
  • If you take anticoagulants/antiplatelet drugs or narrow-therapeutic-index medications (CYP1A2/CYP3A substrates), use only under physician supervision with appropriate monitoring (e.g., INR).
  • If you have or are prone to iron-deficiency anemia, monitor iron studies and CBC, and separate curcumin from iron-containing meals/supplements.
  • Avoid supplemental doses in pregnancy and breastfeeding given inadequate safety data.
  • This is not a performance, hormonal, or body-composition drug; there is no benefit to dose-escalation, and higher/enhanced-absorption dosing may increase hepatotoxic risk. Do not chase a maximal dose.
Evidence

Citations (14)

Every clinical claim above is tied to a primary source. Overall evidence grade B — graded to the best available evidence for its core claims.

  1. 01

    Plain curcumin has poor oral bioavailability due to rapid hepatic/intestinal metabolism, and piperine increases its bioavailability by up to ~2000% in humans (basis for pharmacokinetics and interaction risk).

    RCTPMID 9619120 ↗

  2. 02

    Single oral curcuminoid doses from 500 to 12,000 mg were generally well tolerated in healthy volunteers with only minimal, non-dose-related toxicity, and serum curcumin was largely undetectable, confirming low systemic bioavailability.

    RCTPMID 16545122 ↗

  3. 03

    Turmeric/curcumin can cause idiosyncratic, usually hepatocellular drug-induced liver injury with 1-4 month latency, hospitalization, and death from acute liver failure, strongly linked to HLA-B*35:01 and to piperine-containing products.

    Case seriesPMID 36252717 ↗

  4. 04

    High-bioavailability, high-dose curcumin/Curcuma longa supplements are associated with acute (including cholestatic) hepatitis in pharmacovigilance data and pooled case reports.

    Case seriesPMID 32656820 ↗

  5. 05

    A curcumin supplement caused hepatocellular DILI with AST/ALT >20x upper limit of normal and probable RUCAM causality, resolving after discontinuation.

    Case reportPMID 31781418 ↗

  6. 06

    Turmeric supplement use was associated with acute hepatotoxicity and jaundice in a middle-aged patient.

    Case reportPMID 32037709 ↗

  7. 07

    Curcumin/turmeric supplementation significantly reduces CRP, TNF-alpha and IL-6 and improves antioxidant markers (TAC, SOD, MDA) in a GRADE-assessed meta-analysis of 66 RCTs.

    Meta-analysisPMID 36804260 ↗

  8. 08

    Curcumin supplementation significantly decreases IL-6, hs-CRP and malondialdehyde in a meta-analysis of RCTs.

    Meta-analysisPMID 30402990 ↗

  9. 09

    Across 29 RCTs in arthritis (doses 120-1500 mg for 4-36 weeks), curcumin/Curcuma longa extract improved pain and inflammation with good safety, though evidence quality was low.

    Meta-analysisPMID 35935936 ↗

  10. 10

    In type 2 diabetes, curcumin significantly lowered fasting blood glucose, HbA1c, and CRP versus placebo in a meta-analysis of 18 trials.

    Meta-analysisPMID 39683570 ↗

  11. 11

    Curcumin improves endothelial function and lowers diastolic blood pressure and pulse wave velocity (with improved FMD and reduced VCAM-1) but does not significantly change systolic blood pressure, in an umbrella meta-analysis.

    Meta-analysisPMID 39265778 ↗

  12. 12

    In knee osteoarthritis, curcumin 500 mg three times daily had efficacy comparable to diclofenac with significantly fewer adverse events (13% vs 38%) and reduced flatulence.

    RCTPMID 30975196 ↗

  13. 13

    Curcumin inhibits CYP1A2 and CYP3A activity and modifies warfarin-induced CYP regulation, providing a mechanistic basis for potential anticoagulant/drug interactions (preclinical, in vitro).

    PreclinicalPMID 35695287 ↗

  14. 14

    Curcumin acts as an iron chelator and can lower iron stores and cause mild anemia, suggesting it may worsen iron-deficiency anemia (preclinical mouse model).

    PreclinicalPMID 31026259 ↗

Last reviewed 2026-07-06 · Verified against PubMed · Educational, not medical advice